Relay Therapeutics, Inc.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercial

News & analytics is part of Premium.

Every headline runs through our finance-grade sentiment engine, so you see the mood of the market on each ticker before you read a single article. Plus the full analyst consensus and target-price upside, refreshed daily.

$5.99/mo · Cancel anytime

Technical readouts are part of Premium.

See exactly where the price sits versus its 150-day moving average, the live RSI reading, MACD momentum, and volume context, for any ticker, every day.

$5.99/mo · Cancel anytime